Next Article in Journal
Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer
Next Article in Special Issue
The Endothelium as a Driver of Liver Fibrosis and Regeneration
Previous Article in Journal
IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells
Previous Article in Special Issue
Relationship between Heart Disease and Liver Disease: A Two-Way Street
Review

Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives

by 1,2,†, 1,2,† and 1,2,3,*
1
Université de Strasbourg, 67000 Strasbourg, France
2
Institut de Recherche sur les Maladies Virales et Hépatiques U1110, 67000 Strasbourg, France
3
Pôle Hepato-digestif, Institut Hopitalo-Universitaire, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2020, 9(4), 875; https://doi.org/10.3390/cells9040875
Received: 24 February 2020 / Revised: 28 March 2020 / Accepted: 1 April 2020 / Published: 3 April 2020
Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global health. Correlating with liver disease progression, fibrosis is a key factor for liver disease outcome and risk of hepatocellular carcinoma (HCC). Despite different mechanism of primary liver injury and disease-specific cell responses, the progression of fibrotic liver disease follows shared patterns across the main liver disease etiologies. Scientific discoveries within the last decade have transformed the understanding of the mechanisms of liver fibrosis. Removal or elimination of the causative agent such as control or cure of viral infection has shown that liver fibrosis is reversible. However, reversal often occurs too slowly or too infrequent to avoid life-threatening complications particularly in advanced fibrosis. Thus, there is a huge unmet medical need for anti-fibrotic therapies to prevent liver disease progression and HCC development. However, while many anti-fibrotic candidate agents have shown robust effects in experimental animal models, their anti-fibrotic effects in clinical trials have been limited or absent. Thus, no approved therapy exists for liver fibrosis. In this review we summarize cellular drivers and molecular mechanisms of fibrogenesis in chronic liver diseases and discuss their impact for the development of urgently needed anti-fibrotic therapies. View Full-Text
Keywords: Hepatic stellate cell; liver myofibroblast; Kupffer cell; liver cirrhosis; anti-fibrotics; TGF-β; PDGF Hepatic stellate cell; liver myofibroblast; Kupffer cell; liver cirrhosis; anti-fibrotics; TGF-β; PDGF
Show Figures

Figure 1

MDPI and ACS Style

Roehlen, N.; Crouchet, E.; Baumert, T.F. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020, 9, 875. https://doi.org/10.3390/cells9040875

AMA Style

Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 2020; 9(4):875. https://doi.org/10.3390/cells9040875

Chicago/Turabian Style

Roehlen, Natascha, Emilie Crouchet, and Thomas F. Baumert. 2020. "Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives" Cells 9, no. 4: 875. https://doi.org/10.3390/cells9040875

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop